Summary
Elevance Health, Inc. (ELV) filed an 8-K on February 26, 2026, primarily announcing a significant leadership transition and reaffirming its financial guidance for the full year 2026. Peter D. Haytaian will be stepping down from his role as Executive Vice President and President of Carelon, effective May 4, 2026, to focus on family commitments. He will remain with the company as a Special Advisor through the end of 2026 to ensure a smooth transition and operational continuity. In addition to the management change, Elevance Health reaffirmed its 2026 financial outlook. The company anticipates full-year 2026 earnings per diluted share to be at least $22.30, which includes an estimated $3.20 per diluted share in net unfavorable items. Excluding these items, the adjusted earnings per diluted share are projected to be at least $25.50. The company also reiterated its guidance for the full-year 2026 benefit expense ratio, maintaining it at 90.2% with a tolerance of plus or minus 50 basis points. Investors should monitor the succession plan for Carelon and the ongoing execution against these financial targets.
Key Highlights
- 1Peter D. Haytaian to transition from EVP and President of Carelon to Special Advisor role effective May 4, 2026, through December 31, 2026, for leadership transition support.
- 2Mr. Haytaian's departure is for family commitments and not due to any disagreement with the Company.
- 3Elevance Health reaffirms its 2026 earnings per diluted share guidance of at least $22.30.
- 4The reaffirmed 2026 earnings guidance includes approximately $3.20 per diluted share of net unfavorable items.
- 5Excluding unfavorable items, adjusted 2026 earnings per diluted share are expected to be at least $25.50.
- 6The company reaffirms its full-year 2026 benefit expense ratio guidance of 90.2% +/- 50 basis points.